Skip to main content
Pharmaron Beijing Co., Ltd. logo

Pharmaron Beijing Co., Ltd. — Investor Relations & Filings

Ticker · 300759 ISIN · CNE100003JW4 LEI · 300300JYXHGVS5SNGG54 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 1,320 across all filing types
Latest filing 2026-05-22 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 300759

About Pharmaron Beijing Co., Ltd.

https://www.pharmaron.cn

Pharmaron Beijing Co., Ltd. is a premier R&D service provider for the life sciences industry, offering a comprehensive, fully integrated platform for drug discovery, development, and manufacturing. The company supports global pharmaceutical and biotechnology partners through a wide range of services, including laboratory chemistry, biology, DMPK, pharmacology, and safety assessment. Its capabilities extend to clinical development services and commercial-scale manufacturing for small molecules, biologics, and cell and gene therapies. By leveraging advanced technology and a global network of facilities, the company facilitates the transition of drug candidates from initial concept to market approval, optimizing the efficiency and success of the drug development lifecycle.

Recent filings

Filing Released Lang Actions
关于追加认购投资基金份额的公告
Capital/Financing Update Classification · 93% confidence The document is a formal corporate announcement detailing Kanglong’s additional subscription of investment fund units and the structure of the funding arrangement. It describes a financing/investment transaction (capital deployment into a private equity fund) rather than financial results, board changes, or regulatory certification. This fits the Capital/Financing Update category.
2026-05-22 Chinese
独立董事候选人声明与承诺（李丽华）
Proxy Solicitation & Information Statement Classification · 75% confidence The document is a formal statement and commitment from an independent director candidate (李丽华) of 康龙化成 (北京)新药技术股份有限公司, detailing her qualifications and compliance with relevant laws and stock exchange rules. This type of document is part of proxy materials provided to shareholders ahead of a general meeting to inform and solicit votes for board elections. It is not announcing an appointment (MANG) nor reporting voting results (DVA), but rather providing candidate information for voting. Therefore, it fits the Proxy Solicitation & Information Statement category (PSI).
2026-04-28 Chinese
独立董事提名人声明与承诺（曾劲峰）
Regulatory Filings Classification · 92% confidence The document is a formal announcement by the board nominating and making compliance statements for an independent director candidate under Shenzhen Stock Exchange rules. It contains no financials, voting results, or full meeting materials—it is a regulatory compliance filing of director nomination details. It does not itself effect a board change (MANG is for actual board changes), nor is it a proxy statement in full, so it falls under the general category of Regulatory Filings (RNS).
2026-04-28 Chinese
独立董事候选人声明与承诺（曾劲峰）
Board/Management Information Classification · 87% confidence The document is an official public announcement of an independent director candidate’s declaration and commitment by a Chinese listed company. It relates to the nomination to the board and compliance with legal/regulatory requirements for board membership. This is not an earnings release, financial report, or proxy statement per se, but rather a board/management information disclosure concerning board director nomination. Therefore, it falls under Board/Management Information (MANG).
2026-04-28 Chinese
《公司章程》（2026年4月）
Governance Information Classification · 95% confidence The document is the full Articles of Association (company "章程") of 康龙化成（北京）新药技术股份有限公司, containing detailed corporate governance rules: share structure, shareholder meeting procedures, board composition, management duties, internal audit, amendment procedures, etc. This is not an announcement of a report or a transaction, but the charter itself defining governance practices. It matches the definition of Governance Information (CGR).
2026-04-28 Chinese
独立董事提名人声明与承诺（李丽华）
Board/Management Information Classification · 90% confidence The document is an official announcement by the company regarding the nomination of Ms. Li Lihua as an independent director candidate for the fourth board. It outlines qualifications, legal compliances, and commitments related to her board appointment. This is clearly a Board/Management Information announcement rather than the actual board minutes or a general report publication. Therefore, the most appropriate classification is Board/Management Information (MANG).
2026-04-28 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.